CoChat

Systematic review and meta‐analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present

McClure, David L., Valuck, Robert J, Glanz, Morton, Hokanson, John E. · 2007 · Pharmacoepidemiology and Drug Safety
Cited by 52

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Purpose: Our objective was to determine the association of clinically relevant adverse events from a systematic review and meta‐analysis of statin randomized controlled trials (RCT). Methods: We performed the meta‐analysis in the manner of a Cochrane Collaboration systematic review. Outcomes were discontinuances of therapy or muscle‐related symptoms due to adverse events. We searched for articles from 1982 through June 2006 in MEDLINE and other databases. The main inclusion criteria were double blind, placebo controlled RCTs with a monotherapy intervention of any marketed statin and active surveillance of adverse events. We excluded studies of drug interactions, organ transplants, or exercise, or those not meeting all of the study quality criteria. The primary analysis was a statin formulation stratified fixed‐effect model using Peto odds‐ratios (POR). Secondary analyses explored the stability of the primary results. Results: Over 86 000 study participants from 119 studies were included. Available statins were associated with a lower POR of discontinuance (overall: 0.88 [0.84, 0.93], largest effect with pravastatin: 0.79 [0.74, 0.84]), an elevated POR of rhabdomyolysis (1.59 [0.54, 4.70]) and myositis (2.56 [1.12, 5.85]), and null odds of myalgia (1.09 [0.97, 1.23]). Cerivastatin by comparison demonstrated larger PORs for discontinuances and muscle‐related adverse events. Secondary analyses demonstrated the stability of the results. Conclusions: Overall, discontinuation of statin therapy due to adverse events was no worse than placebo. The risks of muscle‐related adverse events were in general agreement with the known risks of statins. Copyright © 2006 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pds.1341

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

Metadata

Authors
McClure, D. L., Valuck, R. J., Glanz, M., & Hokanson, J. E.
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2006-10-30
Volume
16
Issue
2
Pages
132-143
ISSN
  • 1053-8569 (ISSN-L)
  • 1099-1557
OpenAlex
W2105415378
Cited by
52
References
14
FWCI
0.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.